{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:12:05Z","timestamp":1792548725885,"version":"4.5.0"},"reference-count":175,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The effectiveness of peritoneal dialysis (PD) relies on dialysate-induced solute and water transport across the peritoneal membrane, facilitated by concentration and type of osmotic agents. Standard PD solutions predominantly use glucose as an osmotic agent due to its well-known metabolism, effective ultrafiltration during shorter dwells, and low cost. However, glucose exposure may damage the structure and function of the peritoneal membrane and cause systemic metabolic complications, including insulin resistance and cardiovascular disease, underscoring the need for glucose-sparing strategies with alternative solutions, such as solutions with icodextrin and amino acids as osmotic agents, and glucose-based, less bioincompatible fluids with physiological pH and reduced glucose degradation products. This brief narrative review examines the unwanted effects of glucose-based solutions and the clinical rationales behind glucose-sparing strategies that may reduce these effects and potentially improve clinical outcomes.<\/jats:p>","DOI":"10.1186\/s12882-025-04732-w","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:54:36Z","timestamp":1768272876000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical rationale behind glucose-sparing strategies in peritoneal dialysis: a narrative review"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4269-4293","authenticated-orcid":false,"given":"Bengt","family":"Lindholm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Barbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e8s","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Heider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1217-588X","authenticated-orcid":false,"given":"Rumeyza","family":"Kazancioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Lichodziejewska-Niemierko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9627-908X","authenticated-orcid":false,"given":"Anabela","family":"Malho-Guedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loris","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Parikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Quevedo-Reina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adonay","family":"Santana-Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udaya","family":"Udayaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"issue":"2","key":"4732_CR1","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3747\/pdi.2011.00026","volume":"31","author":"PG Blake","year":"2011","unstructured":"Blake PG, Bargman JM, Brimble KS, et al. Clinical practice guidelines and recommendations on peritoneal Dialysis adequacy 2011. Perit Dial Int. 2011;31(2):218\u201339.","journal-title":"Perit Dial Int"},{"issue":"Suppl 5","key":"4732_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/ndt\/16.suppl_5.61","volume":"16","author":"PG Blake","year":"2001","unstructured":"Blake PG. Integrated end-stage renal disease care: the role of peritoneal dialysis. Nephrol Dial Transpl. 2001;16(Suppl 5):61\u20136.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"4732_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1681\/ASN.2007111188","volume":"20","author":"SP McDonald","year":"2009","unstructured":"McDonald SP, Marshall MR, Johnson DW, Polkinghorne KR. Relationship between dialysis modality and mortality. J Am Soc Nephrol. 2009;20(1):155\u201363.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"4732_CR4","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1681\/ASN.2016010112","volume":"27","author":"R Mehrotra","year":"2016","unstructured":"Mehrotra R, Devuyst O, Davies SJ, Johnson DW. The current state of peritoneal dialysis. J Am Soc Nephrol. 2016;27(11):3238\u201352.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"4732_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrneph.2016.181","volume":"13","author":"PK Li","year":"2017","unstructured":"Li PK, Chow KM, Van de Luijtgaarden MW, et al. Changes in the worldwide epidemiology of peritoneal dialysis. Nat Rev Nephrol. 2017;13(2):90\u2013103.","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"4732_CR6","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1093\/ndt\/gfv132","volume":"30","author":"AC Nadeau-Fredette","year":"2015","unstructured":"Nadeau-Fredette AC, Chan CT, Cho Y, et al. Outcomes of integrated home dialysis care: a multi-centre, multi-national registry study. Nephrol Dial Transpl. 2015;30(11):1897\u2013904.","journal-title":"Nephrol Dial Transpl"},{"issue":"10","key":"4732_CR7","doi-asserted-by":"publisher","first-page":"CD007554","DOI":"10.1002\/14651858.CD007554.pub3","volume":"10","author":"H Htay","year":"2018","unstructured":"Htay H, Johnson DW, Wiggins KJ, et al. Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database Syst Rev. 2018;10(10):CD007554. https:\/\/doi.org\/10.1002\/14651858.CD007554.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9155","key":"4732_CR8","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S0140-6736(98)09410-0","volume":"353","author":"R Gokal","year":"1999","unstructured":"Gokal R, Mallick NP. Peritoneal dialysis. Lancet. 1999;353(9155):823\u20138.","journal-title":"Lancet"},{"issue":"5","key":"4732_CR9","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.ajkd.2003.08.036","volume":"42","author":"I Teitelbaum","year":"2003","unstructured":"Teitelbaum I, Burkart J. Peritoneal dialysis. Am J Kidney Dis. 2003;42(5):1082\u201396.","journal-title":"Am J Kidney Dis"},{"key":"4732_CR10","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.3389\/fphys.2018.01853","volume":"9","author":"M Bartosova","year":"2019","unstructured":"Bartosova M, Schmitt CP. Biocompatible peritoneal dialysis: the target is still way off. Front Physiol. 2019;9:1853. https:\/\/doi.org\/10.3389\/fphys.2018.01853.","journal-title":"Front Physiol"},{"issue":"6","key":"4732_CR11","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1046\/j.1523-1755.1998.00180.x","volume":"54","author":"SJ Davies","year":"1998","unstructured":"Davies SJ, Phillips L, Griffiths AM, Russell LH, Naish PF, Russell GI. What really happens to people on long-term peritoneal dialysis? Kidney Int. 1998;54(6):2207\u201317.","journal-title":"Kidney Int"},{"issue":"1","key":"4732_CR12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.5527\/wjn.v4.i1.92","volume":"4","author":"A Qayyum","year":"2015","unstructured":"Qayyum A, Oei EL, Paudel K, Fan SL. Increasing the use of biocompatible, glucose-free peritoneal dialysis solutions. World J Nephrol. 2015;4(1):92\u20137.","journal-title":"World J Nephrol"},{"issue":"3","key":"4732_CR13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/oxfordjournals.ndt.a027318","volume":"11","author":"SJ Davies","year":"1996","unstructured":"Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transpl. 1996;11(3):498\u2013506.","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"4732_CR14","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1681\/ASN.V132470","volume":"13","author":"JD Williams","year":"2002","unstructured":"Williams JD, Craig KJ, Topley N, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002;13(2):470\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"4732_CR15","doi-asserted-by":"crossref","unstructured":"Williams JD, Craig KJ, von Ruhland C, Topley N, Williams GT; Biopsy Registry Study Group. The natural course of peritoneal membrane biology during peritoneal dialysis. Kidney Int Suppl. 2003;(88):S43\u201349.","DOI":"10.1046\/j.1523-1755.2003.08805.x"},{"issue":"3 Suppl 1","key":"4732_CR16","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1053\/ajkd.2003.50086","volume":"41","author":"A Tauer","year":"2003","unstructured":"Tauer A, Zhang X, Schaub TP, et al. Formation of advanced glycation end products during CAPD. Am J Kidney Dis. 2003;41(3 Suppl 1):S57\u201360.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"4732_CR17","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.0894-0959.2004.17610.x","volume":"17","author":"J Burkart","year":"2004","unstructured":"Burkart J. Metabolic consequences of peritoneal dialysis. Semin Dial. 2004;17(6):498\u2013504.","journal-title":"Semin Dial"},{"issue":"4","key":"4732_CR18","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/ndt\/gfx250","volume":"33","author":"IK Wang","year":"2018","unstructured":"Wang IK, Lin CL, Chen HC, et al. Risk of new-onset diabetes in end-stage renal disease patients undergoing dialysis: analysis from registry data of Taiwan. Nephrol Dial Transpl. 2018;33(4):670\u20135.","journal-title":"Nephrol Dial Transpl"},{"issue":"5","key":"4732_CR19","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3390\/biom10050768","volume":"10","author":"S Roumeliotis","year":"2020","unstructured":"Roumeliotis S, Dounousi E, Salmas M, Eleftheriadis T, Liakopoulos V. Unfavorable effects of peritoneal dialysis solutions on the peritoneal membrane: the role of oxidative stress. Biomolecules. 2020;10(5):768. https:\/\/doi.org\/10.3390\/biom10050768.","journal-title":"Biomolecules"},{"key":"4732_CR20","doi-asserted-by":"publisher","unstructured":"Cho Y, Johnson DW, Craig JC, Strippoli GF, Badve SV, Wiggins KJ. Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database Syst Rev. 2014 Mar 27;(3):CD007554. https:\/\/doi.org\/10.1002\/14651858.CD007554.pub2. Update in: Cochrane Database Syst Rev. 2018;10:CD007554. https:\/\/doi.org\/10.1002\/14651858.CD007554.pub3.","DOI":"10.1002\/14651858.CD007554.pub2"},{"issue":"2","key":"4732_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40620-020-00804-2","volume":"34","author":"M Bonomini","year":"2021","unstructured":"Bonomini M, Zammit V, Divino-Filho JC, et al. The osmo-metabolic approach: a novel and tantalizing glucose-sparing strategy in peritoneal dialysis. J Nephrol. 2021;34(2):503\u201319.","journal-title":"J Nephrol"},{"issue":"13","key":"4732_CR22","doi-asserted-by":"publisher","first-page":"e2991","DOI":"10.1097\/MD.0000000000002991","volume":"95","author":"TI Chang","year":"2016","unstructured":"Chang TI, Ryu DR, Yoo TH, et al. Effect of icodextrin solution on the preservation of residual renal function in peritoneal dialysis patients: A randomized controlled study. Med (Baltim). 2016;95(13):e2991. https:\/\/doi.org\/10.1097\/MD.0000000000002991.","journal-title":"Med (Baltim)"},{"issue":"4","key":"4732_CR23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4103\/ijn.ijn_242_23","volume":"33","author":"IM Alrowiyti","year":"2023","unstructured":"Alrowiyti IM, Bargman J. A review of residual kidney function in peritoneal dialysis patients. Indian J Nephrol. 2023;33(4):239\u201346.","journal-title":"Indian J Nephrol"},{"issue":"8","key":"4732_CR24","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1016\/j.ekir.2025.05.036","volume":"10","author":"E Goffin","year":"2025","unstructured":"Goffin E, B\u00e9chade C, Courivaud C, et al. The double-Icodextrin dose randomized controlled trial of a double icodextrin dose for older patients on incremental continuous ambulatory peritoneal dialysis. Kidney Int Rep. 2025;10(8):2585\u201396.","journal-title":"Kidney Int Rep"},{"key":"4732_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000450690","volume":"189","author":"M Nataatmadja","year":"2017","unstructured":"Nataatmadja M, Cho Y, Johnson DW. Evidence for biocompatible peritoneal dialysis solutions. Contrib Nephrol. 2017;189:91\u2013101.","journal-title":"Contrib Nephrol"},{"issue":"1","key":"4732_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.semnephrol.2016.10.009","volume":"37","author":"MA Bajo","year":"2017","unstructured":"Bajo MA, Del Peso G, Teitelbaum I. Peritoneal membrane preservation. Semin Nephrol. 2017;37(1):77\u201392.","journal-title":"Semin Nephrol"},{"issue":"4","key":"4732_CR27","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nrneph.2012.13","volume":"8","author":"E Garc\u00eda-L\u00f3pez","year":"2012","unstructured":"Garc\u00eda-L\u00f3pez E, Lindholm B, Davies S. An update on peritoneal dialysis solutions. Nat Rev Nephrol. 2012;8(4):224\u201333.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"4732_CR28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ki.1990.231","volume":"38","author":"O Heimb\u00fcrger","year":"1990","unstructured":"Heimb\u00fcrger O, Waniewski J, Werynski A, Tranaeus A, Lindholm B. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int. 1990;38(3):495\u2013506.","journal-title":"Kidney Int"},{"issue":"6","key":"4732_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3747\/pdi.2015.00218","volume":"36","author":"PG Lan","year":"2016","unstructured":"Lan PG, Clayton PA, Johnson DW, et al. Duration of Hemodialysis following peritoneal dialysis cessation in Australia and new zealand: proposal for a standardized definition of technique failure. Perit Dial Int. 2016;36(6):11\u20132.","journal-title":"Perit Dial Int"},{"issue":"3","key":"4732_CR30","first-page":"119","volume":"2","author":"NG De Santo","year":"1979","unstructured":"De Santo NG, Capodicasa G, Senatore R, et al. Glucose utilization from dialysate in patients on continuous ambulatory peritoneal dialysis (CAPD). Int J Artif Organs. 1979;2(3):119\u201324.","journal-title":"Int J Artif Organs"},{"key":"4732_CR31","doi-asserted-by":"crossref","unstructured":"Lindholm B, Bergstrom J. Nutritional management of patients undergoing peritoneal dialysis N. Kd, editor, Peritoneal dialysis, Kluwer, Dordecht (1989), pp. 320\u2013328.","DOI":"10.1007\/978-94-009-1085-0_13"},{"issue":"5","key":"4732_CR32","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/ki.1992.196","volume":"41","author":"O Heimb\u00fcrger","year":"1992","unstructured":"Heimb\u00fcrger O, Waniewski J, Werynski A, Lindholm B. A quantitative description of solute and fluid transport during peritoneal dialysis. Kidney Int. 1992;41(5):1320\u201332.","journal-title":"Kidney Int"},{"key":"4732_CR33","doi-asserted-by":"crossref","unstructured":"Holmes C, Mujais S. Glucose sparing in peritoneal dialysis: implications and metrics. Kidney Int Suppl. 2006;(103):S104\u2013109.","DOI":"10.1038\/sj.ki.5001924"},{"key":"4732_CR34","doi-asserted-by":"crossref","unstructured":"Mujais S, Vonesh E. Profiling of peritoneal ultrafiltration. Kidney Int Suppl. 2002;(81):S17\u201322.","DOI":"10.1046\/j.1523-1755.62.s81.4.x"},{"issue":"4","key":"4732_CR35","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/ki.1981.53","volume":"19","author":"GP Grodstein","year":"1981","unstructured":"Grodstein GP, Blumenkrantz MJ, Kopple JD, Moran JK, Coburn JW. Glucose absorption during continuous ambulatory peritoneal dialysis. Kidney Int. 1981;19(4):564\u20137.","journal-title":"Kidney Int"},{"issue":"5","key":"4732_CR36","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1681\/ASN.V1251046","volume":"12","author":"SJ Davies","year":"2001","unstructured":"Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol. 2001;12(5):1046\u201351.","journal-title":"J Am Soc Nephrol"},{"key":"4732_CR37","doi-asserted-by":"crossref","unstructured":"Duong U, Mehrotra R, Molnar MZ, et al. Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus. Clin J Am Soc Nephrol. 2011 y;6(5):1041\u20131048.","DOI":"10.2215\/CJN.08921010"},{"issue":"3","key":"4732_CR38","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3747\/pdi.2015.00251","volume":"36","author":"MB Rivara","year":"2016","unstructured":"Rivara MB, Mehrotra R. New-Onset diabetes in peritoneal dialysis patients - Which predictors really matter? Perit Dial Int. 2016;36(3):243\u20136.","journal-title":"Perit Dial Int"},{"issue":"5","key":"4732_CR39","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/ki.1993.347","volume":"44","author":"J Bergstr\u00f6m","year":"1993","unstructured":"Bergstr\u00f6m J, F\u00fcrst P, Alvestrand A, Lindholm B. Protein and energy intake, nitrogen balance and nitrogen losses in patients treated with continuous ambulatory peritoneal dialysis. Kidney Int. 1993;44(5):1048\u201357.","journal-title":"Kidney Int"},{"key":"4732_CR40","first-page":"S39","volume":"40","author":"J Bergstr\u00f6m","year":"1993","unstructured":"Bergstr\u00f6m J, Lindholm B. Nutrition and adequacy of dialysis. How do Hemodialysis and CAPD compare? Kidney Int Suppl. 1993;40:S39\u201350.","journal-title":"Kidney Int Suppl"},{"issue":"12","key":"4732_CR41","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.34067\/KID.0004722020","volume":"1","author":"SK Kotla","year":"2020","unstructured":"Kotla SK, Saxena A, Saxena R. A model to estimate glucose absorption in peritoneal dialysis: A pilot study. Kidney360. 2020;1(12):1373\u20139.","journal-title":"Kidney360"},{"issue":"5\u20136","key":"4732_CR42","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1159\/000170024","volume":"9","author":"EF Vonesh","year":"1991","unstructured":"Vonesh EF, Lysaght MJ, Moran J, Farrell P. Kinetic modeling as a prescription aid in peritoneal dialysis. Blood Purif. 1991;9(5\u20136):246\u201370.","journal-title":"Blood Purif"},{"key":"4732_CR43","doi-asserted-by":"publisher","first-page":"880097","DOI":"10.3389\/fneph.2022.880097","volume":"2","author":"JK Ng","year":"2022","unstructured":"Ng JK, Than WH, Szeto CC, Obesity. Weight Gain, and fluid overload in peritoneal dialysis. Front Nephrol. 2022;2:880097. https:\/\/doi.org\/10.3389\/fneph.2022.880097.","journal-title":"Front Nephrol"},{"issue":"6","key":"4732_CR44","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1159\/000345476","volume":"36","author":"KL Lentine","year":"2012","unstructured":"Lentine KL, Delos Santos R, Axelrod D, Schnitzler MA, Brennan DC, Tuttle-Newhall JE. Obesity and kidney transplant candidates: how big is too big for transplantation? Am J Nephrol. 2012;36(6):575\u201386.","journal-title":"Am J Nephrol"},{"issue":"3","key":"4732_CR45","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1053\/j.jrn.2013.01.019","volume":"23","author":"YL Kim","year":"2013","unstructured":"Kim YL, Cho JH, Choi JY, Kim CD, Park SH. Systemic and local impact of glucose and glucose degradation products in peritoneal dialysis solution. J Ren Nutr. 2013;23(3):218\u201322.","journal-title":"J Ren Nutr"},{"issue":"4","key":"4732_CR46","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1053\/j.ajkd.2007.01.018","volume":"49","author":"CC Szeto","year":"2007","unstructured":"Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK. New-onset hyperglycemia in nondiabetic Chinese patients started on peritoneal dialysis. Am J Kidney Dis. 2007;49(4):524\u201332.","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"4732_CR47","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1093\/ndt\/gfv247","volume":"30","author":"TP de Moraes","year":"2015","unstructured":"de Moraes TP, Andreoli MC, Canziani ME, et al. Icodextrin reduces insulin resistance in non-diabetic patients undergoing automated peritoneal dialysis: results of a randomized controlled trial (STARCH). Nephrol Dial Transpl. 2015;30(11):1905\u201311.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"4732_CR48","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1046\/j.1523-1755.2003.00209.x","volume":"64","author":"J Marshall","year":"2003","unstructured":"Marshall J, Jennings P, Scott A, Fluck RJ, McIntyre CW. Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int. 2003;64(4):1480\u20136.","journal-title":"Kidney Int"},{"issue":"5","key":"4732_CR49","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1177\/08968608211047787","volume":"42","author":"J Williams","year":"2022","unstructured":"Williams J, Gilchrist M, Strain WD, Fraser D, Shore A. 24-h glycaemic profiles in peritoneal dialysis patients and non-dialysis controls with advanced kidney disease. Perit Dial Int. 2022;42(5):497\u2013504.","journal-title":"Perit Dial Int"},{"issue":"Suppl 2","key":"4732_CR50","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.1177\/089686080902902S28","volume":"29","author":"PC Fortes","year":"2009","unstructured":"Fortes PC, de Moraes TP, Mendes JG, Stinghen AE, Ribeiro SC, Pecoits-Filho R. Insulin resistance and glucose homeostasis in peritoneal dialysis. Perit Dial Int. 2009;29(Suppl 2):S145\u2013148.","journal-title":"Perit Dial Int"},{"issue":"8","key":"4732_CR51","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1093\/ndt\/gfz116","volume":"35","author":"C Xue","year":"2020","unstructured":"Xue C, Gu YY, Cui CJ, et al. New-onset glucose disorders in peritoneal dialysis patients: a meta-analysis and systematic review. Nephrol Dial Transpl. 2020;35(8):1412\u20139.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"4732_CR52","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12882-020-01820-x","volume":"21","author":"Y Shi","year":"2020","unstructured":"Shi Y, Cai J, Shi C, Liu C, Li Z. Incidence and mortality of new-onset glucose disorders in peritoneal dialysis patients in china: a meta-analysis. BMC Nephrol. 2020;21(1):152. https:\/\/doi.org\/10.1186\/s12882-020-01820-x.","journal-title":"BMC Nephrol"},{"issue":"3","key":"4732_CR53","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/ndt\/gfl654","volume":"22","author":"NM Selby","year":"2007","unstructured":"Selby NM, Fialova J, Burton JO, McIntyre CW. The haemodynamic and metabolic effects of hypertonic-glucose and amino-acid-based peritoneal dialysis fluids. Nephrol Dial Transpl. 2007;22(3):870\u20139.","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"4732_CR54","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/08860220701810307","volume":"30","author":"DR da Silva","year":"2008","unstructured":"da Silva DR, Figueiredo AE, Antonello IC, de Poli CE, d\u2019Avila DO. Solutes transport characteristics in peritoneal dialysis: variations in glucose and insulin serum levels. Ren Fail. 2008;30(2):175\u20139.","journal-title":"Ren Fail"},{"key":"4732_CR55","first-page":"11","volume":"31","author":"I Oba","year":"2015","unstructured":"Oba I, Mori T, Chida M, et al. Glucose and insulin response to peritoneal dialysis fluid in diabetic and nondiabetic peritoneal dialysis patients. Adv Perit Dial. 2015;31:11\u20136.","journal-title":"Adv Perit Dial"},{"issue":"6","key":"4732_CR56","doi-asserted-by":"publisher","first-page":"e0155564","DOI":"10.1371\/journal.pone.0155564","volume":"11","author":"M Lambie","year":"2016","unstructured":"Lambie M, Chess J, Do JY, et al. Peritoneal dialysate glucose load and systemic glucose metabolism in Non-Diabetics: results from the GLOBAL fluid cohort study. PLoS ONE. 2016;11(6):e0155564. https:\/\/doi.org\/10.1371\/journal.pone.0155564.","journal-title":"PLoS ONE"},{"issue":"4","key":"4732_CR57","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.ekir.2023.01.040","volume":"8","author":"P Wijewickrama","year":"2023","unstructured":"Wijewickrama P, Williams J, Bain S, et al. Narrative review of glycemic management in people with diabetes on peritoneal dialysis. Kidney Int Rep. 2023;8(4):700\u201314. https:\/\/doi.org\/10.1016\/j.ekir.2023.01.040.","journal-title":"Kidney Int Rep"},{"issue":"5","key":"4732_CR58","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1161\/01.ATV.0000122852.22604.78","volume":"24","author":"A Ceriello","year":"2004","unstructured":"Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004;24(5):816\u201323.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"4732_CR59","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12933-018-0762-4","volume":"17","author":"V Ormazabal","year":"2018","unstructured":"Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zu\u00f1iga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):122. https:\/\/doi.org\/10.1186\/s12933-018-0762-4.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"4732_CR60","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3390\/ijms21051835","volume":"21","author":"A Poznyak","year":"2020","unstructured":"Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The diabetes Mellitus-Atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. 2020;21(5):1835. https:\/\/doi.org\/10.3390\/ijms21051835.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4732_CR61","doi-asserted-by":"publisher","first-page":"e3502","DOI":"10.1002\/dmrr.3502","volume":"38","author":"JL Silveira Rossi","year":"2022","unstructured":"Silveira Rossi JL, Barbalho SM, Reverete de Araujo R, Bechara MD, Sloan KP, Sloan LA. Metabolic syndrome and cardiovascular diseases: going beyond traditional risk factors. Diabetes Metab Res Rev. 2022;38(3):e3502. https:\/\/doi.org\/10.1002\/dmrr.3502.","journal-title":"Diabetes Metab Res Rev"},{"issue":"9","key":"4732_CR62","doi-asserted-by":"publisher","first-page":"7898","DOI":"10.3390\/ijms24097898","volume":"24","author":"SK Masenga","year":"2023","unstructured":"Masenga SK, Kabwe LS, Chakulya M, Kirabo A. Mechanisms of oxidative stress in metabolic syndrome. Int J Mol Sci. 2023;24(9):7898. https:\/\/doi.org\/10.3390\/ijms24097898.","journal-title":"Int J Mol Sci"},{"issue":"19","key":"4732_CR63","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.3390\/cells11193034","volume":"11","author":"AV Poznyak","year":"2022","unstructured":"Poznyak AV, Litvinova L, Poggio P, Sukhorukov VN, Orekhov AN. Effect of glucose levels on cardiovascular risk. Cells. 2022;11(19):3034. https:\/\/doi.org\/10.3390\/cells11193034.","journal-title":"Cells"},{"issue":"11","key":"4732_CR64","doi-asserted-by":"publisher","first-page":"9352","DOI":"10.3390\/ijms24119352","volume":"24","author":"P Gonz\u00e1lez","year":"2023","unstructured":"Gonz\u00e1lez P, Lozano P, Ros G, Solano F. Hyperglycemia and oxidative stress: an Integral, updated and critical overview of their metabolic interconnections. Int J Mol Sci. 2023;24(11):9352. https:\/\/doi.org\/10.3390\/ijms24119352.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4732_CR65","doi-asserted-by":"publisher","first-page":"R453","DOI":"10.1016\/j.cub.2014.03.034","volume":"24","author":"M Schieber","year":"2014","unstructured":"Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol. 2014;24(10):R453\u201362.","journal-title":"Curr Biol"},{"key":"4732_CR66","doi-asserted-by":"publisher","first-page":"360438","DOI":"10.1155\/2014\/360438","volume":"2014","author":"A Ayala","year":"2014","unstructured":"Ayala A, Mu\u00f1oz MF, Arg\u00fcelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev. 2014;2014:360438. https:\/\/doi.org\/10.1155\/2014\/360438.","journal-title":"Oxid Med Cell Longev"},{"issue":"7","key":"4732_CR67","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3390\/antiox10071041","volume":"10","author":"V Ravarotto","year":"2021","unstructured":"Ravarotto V, Bertoldi G, Innico G, Gobbi L, Cal\u00f2 LA. The pivotal role of oxidative stress in the pathophysiology of Cardiovascular-Renal remodeling in kidney disease. Antioxid (Basel). 2021;10(7):1041. https:\/\/doi.org\/10.3390\/antiox10071041.","journal-title":"Antioxid (Basel)"},{"issue":"5","key":"4732_CR68","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3390\/jcm9051328","volume":"9","author":"TM Seccia","year":"2020","unstructured":"Seccia TM, Rigato M, Ravarotto V, Cal\u00f2 LA. ROCK (RhoA\/Rho Kinase) in Cardiovascular-Renal pathophysiology: A review of new advancements. J Clin Med. 2020;9(5):1328. https:\/\/doi.org\/10.3390\/jcm9051328.","journal-title":"J Clin Med"},{"issue":"5","key":"4732_CR69","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/sdi.12818","volume":"32","author":"S Roumeliotis","year":"2019","unstructured":"Roumeliotis S, Eleftheriadis T, Liakopoulos V. Is oxidative stress an issue in peritoneal dialysis? Semin Dial. 2019;32(5):463\u20136.","journal-title":"Semin Dial"},{"key":"4732_CR70","doi-asserted-by":"publisher","first-page":"3494867","DOI":"10.1155\/2017\/3494867","volume":"2017","author":"V Liakopoulos","year":"2017","unstructured":"Liakopoulos V, Roumeliotis S, Gorny X, Eleftheriadis T, Mertens PR. Oxidative stress in patients undergoing peritoneal dialysis: A current review of the literature. Oxid Med Cell Longev. 2017;2017:3494867. https:\/\/doi.org\/10.1155\/2017\/3494867.","journal-title":"Oxid Med Cell Longev"},{"issue":"9","key":"4732_CR71","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3390\/life14091173","volume":"14","author":"A Basso","year":"2024","unstructured":"Basso A, Cacciapuoti M, Stefanelli LF, Nalesso F, Cal\u00f2 LA. Glucose-Free solutions mediated Inhibition of oxidative stress and oxidative stress-Related damages in peritoneal dialysis: A promising solution. Life (Basel). 2024;14(9):1173. https:\/\/doi.org\/10.3390\/life14091173.","journal-title":"Life (Basel)"},{"issue":"2","key":"4732_CR72","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1177\/089686080202200209","volume":"22","author":"JB Moberly","year":"2002","unstructured":"Moberly JB, Attman PO, Samuelsson O, Johansson AC, Knight-Gibson C, Alaupovic P. Alterations in lipoprotein composition in peritoneal dialysis patients. Perit Dial Int. 2002;22(2):220\u20138.","journal-title":"Perit Dial Int"},{"key":"4732_CR73","doi-asserted-by":"publisher","first-page":"869899","DOI":"10.3389\/fendo.2022.869899","volume":"13","author":"J Ling","year":"2022","unstructured":"Ling J, Ng JKC, Chan JCN, Chow E. Use of continuous glucose monitoring in the assessment and management of patients with diabetes and chronic kidney disease. Front Endocrinol (Lausanne). 2022;13:869899. https:\/\/doi.org\/10.3389\/fendo.2022.869899.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"4732_CR74","doi-asserted-by":"publisher","first-page":"16394","DOI":"10.1038\/s41598-022-20757-9","volume":"12","author":"JH Lluesa","year":"2022","unstructured":"Lluesa JH, L\u00f3pez-Romero LC, Monz\u00f3 JJB, et al. Lipidic profiles of patients starting peritoneal dialysis suggest an increased cardiovascular risk beyond classical dyslipidemia biomarkers. Sci Rep. 2022;12(1):16394. https:\/\/doi.org\/10.1038\/s41598-022-20757-9.","journal-title":"Sci Rep"},{"issue":"1","key":"4732_CR75","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3747\/pdi.2013.00083","volume":"35","author":"Y Wen","year":"2015","unstructured":"Wen Y, Guo Q, Yang X, et al. High glucose concentrations in peritoneal dialysate are associated with all-cause and cardiovascular disease mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 2015;35(1):70\u20137.","journal-title":"Perit Dial Int"},{"issue":"1","key":"4732_CR76","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/0896860820903655","volume":"41","author":"S Law","year":"2021","unstructured":"Law S, Davenport A. The effect of glucose absorption from peritoneal dialysates on changes in lipid profiles in prevalent peritoneal dialysis patients. Perit Dial Int. 2021;41(1):115\u20137.","journal-title":"Perit Dial Int"},{"issue":"12","key":"4732_CR77","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.2215\/CJN.02140214","volume":"9","author":"D Sharma","year":"2014","unstructured":"Sharma D, Hawkins M, Abramowitz MK. Association of sarcopenia with eGFR and misclassification of obesity in adults with CKD in the united States. Clin J Am Soc Nephrol. 2014;9(12):2079\u201388.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"4732_CR78","doi-asserted-by":"publisher","first-page":"e0176230","DOI":"10.1371\/journal.pone.0176230","volume":"12","author":"VA Souza","year":"2017","unstructured":"Souza VA, Oliveira D, Barbosa SR, et al. Sarcopenia in patients with chronic kidney disease not yet on dialysis: analysis of the prevalence and associated factors. PLoS ONE. 2017;12(4):e0176230. https:\/\/doi.org\/10.1371\/journal.pone.0176230.","journal-title":"PLoS ONE"},{"issue":"3","key":"4732_CR79","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1046\/j.1523-1755.2003.00803.x","volume":"63","author":"K Kalantar-Zadeh","year":"2003","unstructured":"Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63(3):793\u2013808.","journal-title":"Kidney Int"},{"issue":"1","key":"4732_CR80","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/MOL.0000000000000045","volume":"25","author":"V Peev","year":"2014","unstructured":"Peev V, Nayer A, Contreras G. Dyslipidemia, malnutrition, inflammation, cardiovascular disease and mortality in chronic kidney disease. Curr Opin Lipidol. 2014;25(1):54\u201360.","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"4732_CR81","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1053\/j.jrn.2024.05.005","volume":"35","author":"J Wang","year":"2025","unstructured":"Wang J, Zhao J, Li L, et al. Association between peritoneal glucose Absorption, lipid Metabolism, and cardiovascular disease risk in nondiabetic patients on peritoneal dialysis. J Ren Nutr. 2025;35(1):196\u2013206. https:\/\/doi.org\/10.1053\/j.jrn.2024.05.005.","journal-title":"J Ren Nutr"},{"issue":"4","key":"4732_CR82","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1744-9987.2006.00391.x","volume":"10","author":"C Higuchi","year":"2006","unstructured":"Higuchi C, Nishimura H, Sanaka T. Biocompatibility of peritoneal dialysis fluid and influence of compositions on peritoneal fibrosis. Ther Apher Dial. 2006;10(4):372\u20139.","journal-title":"Ther Apher Dial"},{"issue":"3","key":"4732_CR83","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1053\/j.ackd.2007.03.009","volume":"14","author":"CJ Holmes","year":"2007","unstructured":"Holmes CJ. Glucotoxicity in peritoneal dialysis\u2013solutions for the solution! Adv Chronic Kidney Dis. 2007;14(3):269\u201378.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"6","key":"4732_CR84","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.3390\/ijms25063532","volume":"25","author":"M Bonomini","year":"2024","unstructured":"Bonomini M, Masola V, Monaco MP, et al. Coupling osmotic efficacy with biocompatibility in peritoneal dialysis: A stiff challenge. Int J Mol Sci. 2024;25(6):3532. https:\/\/doi.org\/10.3390\/ijms25063532.","journal-title":"Int J Mol Sci"},{"issue":"16","key":"4732_CR85","doi-asserted-by":"publisher","first-page":"8607","DOI":"10.3390\/ijms25168607","volume":"25","author":"Y Ito","year":"2024","unstructured":"Ito Y, Sun T, Tawada M, et al. Pathophysiological mechanisms of peritoneal fibrosis and peritoneal membrane dysfunction in peritoneal dialysis. Int J Mol Sci. 2024;25(16):8607. https:\/\/doi.org\/10.3390\/ijms25168607.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4732_CR86","doi-asserted-by":"publisher","first-page":"244","DOI":"10.2215\/CJN.0000000000000282","volume":"19","author":"J Morelle","year":"2024","unstructured":"Morelle J, Lambie M, \u00d6berg CM, Davies S. The peritoneal membrane and its role in peritoneal dialysis. Clin J Am Soc Nephrol. 2024;19(2):244\u201353.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"4732_CR87","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1681\/ASN.2005020155","volume":"17","author":"V Schwenger","year":"2006","unstructured":"Schwenger V, Morath C, Salava A, et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol. 2006;17(1):199\u2013207.","journal-title":"J Am Soc Nephrol"},{"issue":"Pt B","key":"4732_CR88","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.biocel.2016.04.016","volume":"77","author":"TA Morinelli","year":"2016","unstructured":"Morinelli TA, Luttrell LM, Strungs EG, Ullian ME. Angiotensin II receptors and peritoneal dialysis-induced peritoneal fibrosis. Int J Biochem Cell Biol. 2016;77(Pt B):240\u201350. https:\/\/doi.org\/10.1016\/j.biocel.2016.04.016.","journal-title":"Int J Biochem Cell Biol"},{"issue":"11","key":"4732_CR89","doi-asserted-by":"publisher","first-page":"e31799","DOI":"10.7759\/cureus.31799","volume":"14","author":"S Taheri","year":"2022","unstructured":"Taheri S, Thiagaraj SS, Shukla TS, et al. A review on major pathways leading to peritoneal fibrosis in patients receiving continuous peritoneal dialysis. Cureus. 2022;14(11):e31799. https:\/\/doi.org\/10.7759\/cureus.31799.","journal-title":"Cureus"},{"issue":"13","key":"4732_CR90","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.3390\/jcm12134401","volume":"12","author":"SD Suryantoro","year":"2023","unstructured":"Suryantoro SD, Thaha M, Sutanto H, Firdausa S. Current insights into cellular determinants of peritoneal fibrosis in peritoneal dialysis: A narrative review. J Clin Med. 2023;12(13):4401. https:\/\/doi.org\/10.3390\/jcm12134401.","journal-title":"J Clin Med"},{"issue":"6","key":"4732_CR91","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/ki.2010.186","volume":"78","author":"ML Lambie","year":"2010","unstructured":"Lambie ML, John B, Mushahar L, Huckvale C, Davies SJ. The peritoneal osmotic conductance is low well before the diagnosis of encapsulating peritoneal sclerosis is made. Kidney Int. 2010;78(6):611\u20138. https:\/\/doi.org\/10.1038\/ki.2010.186.","journal-title":"Kidney Int"},{"issue":"1","key":"4732_CR92","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","volume":"166","author":"MA Nieto","year":"2016","unstructured":"Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. Cell. 2016;166(1):21\u201345.","journal-title":"Cell"},{"issue":"9","key":"4732_CR93","doi-asserted-by":"publisher","first-page":"4831","DOI":"10.3390\/ijms23094831","volume":"23","author":"V Masola","year":"2022","unstructured":"Masola V, Bonomini M, Borrelli S, et al. Fibrosis of peritoneal membrane as target of new therapies in peritoneal dialysis. Int J Mol Sci. 2022;23(9):4831. https:\/\/doi.org\/10.3390\/ijms23094831.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"4732_CR94","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.3390\/ijms22094739","volume":"22","author":"Y Lho","year":"2021","unstructured":"Lho Y, Do JY, Heo JY, Kim AY, Kim SW, Kang SH. Effects of TGF-\u03b21 receptor inhibitor GW788388 on the epithelial to mesenchymal transition of peritoneal mesothelial cells. Int J Mol Sci. 2021;22(9):4739. https:\/\/doi.org\/10.3390\/ijms22094739.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"4732_CR95","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1093\/ndt\/gfs314","volume":"27","author":"DW Johnson","year":"2012","unstructured":"Johnson DW, Brown FG, Clarke M, et al. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the BalANZ trial. Nephrol Dial Transpl. 2012;27(12):4445\u201353. https:\/\/doi.org\/10.1093\/ndt\/gfs314.","journal-title":"Nephrol Dial Transpl"},{"issue":"11","key":"4732_CR96","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.2215\/CJN.03470315","volume":"10","author":"R Mehrotra","year":"2015","unstructured":"Mehrotra R, Ravel V, Streja E, et al. Peritoneal equilibration test and patient outcomes. Clin J Am Soc Nephrol. 2015;10(11):1990\u20132001.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"4732_CR97","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3747\/pdi.2017.00223","volume":"38","author":"MS Nataatmadja","year":"2018","unstructured":"Nataatmadja MS, Johnson DW, Pascoe EM, Darssan D, Hawley CM, Cho Y. BalANZ trial Investigators. Associations between peritoneal glucose exposure, glucose degradation product exposure, and peritoneal membrane transport characteristics in peritoneal dialysis patients: secondary analysis of the BalANZ trial. Perit Dial Int. 2018;38(5):349\u201355.","journal-title":"Perit Dial Int"},{"issue":"7","key":"4732_CR98","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3747\/pdi.2012.00331","volume":"34","author":"EY Seo","year":"2014","unstructured":"Seo EY, An SH, Cho JH, et al. Effect of biocompatible peritoneal dialysis solution on residual renal function: a systematic review of randomized controlled trials. Perit Dial Int. 2014;34(7):724\u201331.","journal-title":"Perit Dial Int"},{"issue":"8","key":"4732_CR99","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.2215\/CJN.05410514","volume":"10","author":"S Yohanna","year":"2015","unstructured":"Yohanna S, Alkatheeri AM, Brimble SK, et al. Effect of Neutral-pH, Low-glucose degradation product peritoneal dialysis solutions on residual renal function, urine volume, and ultrafiltration: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2015;10(8):1380\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"4732_CR100","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3747\/pdi.2011.00279","volume":"33","author":"KH Cho","year":"2013","unstructured":"Cho KH, Do JY, Park JW, Yoon KW, Kim YL. The effect of low-GDP solution on ultrafiltration and solute transport in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 2013;33(4):382\u201390. Erratum in: Perit Dial Int. 2013;33(5):473\u2013474.","journal-title":"Perit Dial Int"},{"issue":"10","key":"4732_CR101","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1681\/ASN.2021010080","volume":"32","author":"RT Krediet","year":"2021","unstructured":"Krediet RT. Acquired decline in ultrafiltration in peritoneal dialysis: the role of glucose. J Am Soc Nephrol. 2021;32(10):2408\u201315.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"4732_CR102","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00441-016-2461-3","volume":"365","author":"IA Darby","year":"2016","unstructured":"Darby IA, Hewitson TD. Hypoxia in tissue repair and fibrosis. Cell Tissue Res. 2016;365(3):553\u201362.","journal-title":"Cell Tissue Res"},{"issue":"2","key":"4732_CR103","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3747\/pdi.2012.00189","volume":"34","author":"AM Coester","year":"2014","unstructured":"Coester AM, Smit W, Struijk DG, Parikova A, Krediet RT. Longitudinal analysis of peritoneal fluid transport and its determinants in a cohort of incident peritoneal dialysis patients. Perit Dial Int. 2014;34(2):195\u2013203.","journal-title":"Perit Dial Int"},{"issue":"11","key":"4732_CR104","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1111\/cas.12522","volume":"105","author":"N Fujikuni","year":"2014","unstructured":"Fujikuni N, Yamamoto H, Tanabe K, et al. Hypoxia-mediated CD24 expression is correlated with gastric cancer aggressiveness by promoting cell migration and invasion. Cancer Sci. 2014;105(11):1411\u201320.","journal-title":"Cancer Sci"},{"issue":"1","key":"4732_CR105","doi-asserted-by":"publisher","first-page":"F229","DOI":"10.1152\/ajprenal.00274.2019","volume":"318","author":"A Parikova","year":"2020","unstructured":"Parikova A, Hruba P, Krejcik Z, et al. Peritoneal dialysis induces alterations in the transcriptome of peritoneal cells before detectible peritoneal functional changes. Am J Physiol Ren Physiol. 2020;318(1):F229\u201337.","journal-title":"Am J Physiol Ren Physiol"},{"key":"4732_CR106","doi-asserted-by":"publisher","unstructured":"Han Q, Orr ZJ, Desouza GK, Bagi Z, Rudic RD. GDP in dialysis associates with peritoneal vascular remodeling in kidney disease. Circ Res. 2021;129(5):527\u2013529. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.319785. Erratum in: Circ Res. 2021;129(7):e145. https:\/\/doi.org\/10.1161\/RES.0000000000000508.","DOI":"10.1161\/CIRCRESAHA.121.319785"},{"key":"4732_CR107","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3389\/fphys.2017.00379","volume":"8","author":"F Simon","year":"2017","unstructured":"Simon F, Tapia P, Armisen R, et al. Human peritoneal mesothelial cell death induced by High-glucose hypertonic solution involves Ca2\u2009+\u2009and Na\u2009+\u2009Ions and oxidative stress with the participation of PKC\/NOX2 and PI3K\/Akt pathways. Front Physiol. 2017;8:379. https:\/\/doi.org\/10.3389\/fphys.2017.00379.","journal-title":"Front Physiol"},{"issue":"4","key":"4732_CR108","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1042\/CS20110340","volume":"122","author":"M Mihara","year":"2012","unstructured":"Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6\/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2012;122(4):143\u201359.","journal-title":"Clin Sci (Lond)"},{"key":"4732_CR109","doi-asserted-by":"publisher","first-page":"110289","DOI":"10.1016\/j.cbi.2022.110289","volume":"369","author":"LL Ren","year":"2023","unstructured":"Ren LL, Li XJ, Duan TT, et al. Transforming growth factor-\u03b2 signaling: from tissue fibrosis to therapeutic opportunities. Chem Biol Interact. 2023;369:110289. https:\/\/doi.org\/10.1016\/j.cbi.2022.110289.","journal-title":"Chem Biol Interact"},{"issue":"1","key":"4732_CR110","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.yexcr.2016.01.014","volume":"341","author":"J Wu","year":"2016","unstructured":"Wu J, Li X, Zhu G, Zhang Y, He M, Zhang J. The role of Resveratrol-induced mitophagy\/autophagy in peritoneal mesothelial cells inflammatory injury via NLRP3 inflammasome activation triggered by mitochondrial ROS. Exp Cell Res. 2016;341(1):42\u201353.","journal-title":"Exp Cell Res"},{"key":"4732_CR111","doi-asserted-by":"publisher","first-page":"675363","DOI":"10.3389\/fmed.2021.675363","volume":"8","author":"Q Luo","year":"2021","unstructured":"Luo Q, Hu Q, Zheng Q, et al. Enhanced mPGES-1 contributes to PD-Related peritoneal fibrosis via activation of the NLRP3 inflammasome. Front Med (Lausanne). 2021;8:675363. https:\/\/doi.org\/10.3389\/fmed.2021.675363.","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"4732_CR112","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1093\/ndt\/gfh278","volume":"19","author":"Y Yamaji","year":"2004","unstructured":"Yamaji Y, Nakazato Y, Oshima N, Hayashi M, Saruta T. Oxidative stress induced by iron released from transferrin in low pH peritoneal dialysis solution. Nephrol Dial Transpl. 2004;19(10):2592\u20137.","journal-title":"Nephrol Dial Transpl"},{"issue":"11","key":"4732_CR113","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1093\/ndt\/gfh478","volume":"19","author":"S Ogata","year":"2004","unstructured":"Ogata S, Naito T, Yorioka N, Kiribayashi K, Kuratsune M, Kohno N. Effect of lactate and bicarbonate on human peritoneal mesothelial cells, fibroblasts and vascular endothelial cells, and the role of basic fibroblast growth factor. Nephrol Dial Transpl. 2004;19(11):2831\u20137.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"4732_CR114","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1111\/j.1523-1755.2005.00237.x","volume":"67","author":"S Mortier","year":"2005","unstructured":"Mortier S, Faict D, Lameire NH, De Vriese AS. Benefits of switching from a conventional to a low-GDP bicarbonate\/lactate-buffered dialysis solution in a rat model. Kidney Int. 2005;67(4):1559\u201365.","journal-title":"Kidney Int"},{"issue":"4","key":"4732_CR115","doi-asserted-by":"publisher","first-page":"C215","DOI":"10.1152\/ajpcell.00133.2014","volume":"309","author":"W Xiao","year":"2015","unstructured":"Xiao W, Ren M, Zhang C, Li S, An W. Amelioration of nonalcoholic fatty liver disease by hepatic stimulator substance via preservation of carnitine palmitoyl transferase-1 activity. Am J Physiol Cell Physiol. 2015;309(4):C215\u2013227.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"3","key":"4732_CR116","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jacbts.2019.02.003","volume":"4","author":"W Wang","year":"2019","unstructured":"Wang W, Zhang L, Battiprolu PK, et al. Malonyl coa decarboxylase inhibition improves cardiac function post-myocardial infarction. JACC Basic Transl Sci. 2019;4(3):385\u2013400.","journal-title":"JACC Basic Transl Sci"},{"issue":"3","key":"4732_CR117","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.bbrc.2019.06.055","volume":"516","author":"HJ Hu","year":"2019","unstructured":"Hu HJ, Zhang C, Tang ZH, Qu SL, Jiang ZS. Regulating the Warburg effect on metabolic stress and myocardial fibrosis remodeling and atrial intracardiac waveform activity induced by atrial fibrillation. Biochem Biophys Res Commun. 2019;516(3):653\u201360.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"4732_CR118","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3390\/ijms21010234","volume":"21","author":"B Pajak","year":"2019","unstructured":"Pajak B, Siwiak E, So\u0142tyka M, et al. Int J Mol Sci. 2019;21(1):234. https:\/\/doi.org\/10.3390\/ijms21010234.","journal-title":"Int J Mol Sci"},{"issue":"495","key":"4732_CR119","doi-asserted-by":"publisher","first-page":"eaav5341","DOI":"10.1126\/scitranslmed.aav5341","volume":"11","author":"M Si","year":"2019","unstructured":"Si M, Wang Q, Li Y, et al. Inhibition of hyperglycolysis in mesothelial cells prevents peritoneal fibrosis. Sci Transl Med. 2019;11(495):eaav5341. https:\/\/doi.org\/10.1126\/scitranslmed.aav5341.","journal-title":"Sci Transl Med"},{"issue":"1","key":"4732_CR120","doi-asserted-by":"publisher","first-page":"20180103","DOI":"10.1515\/pp-2018-0103","volume":"3","author":"RB Wilson","year":"2018","unstructured":"Wilson RB. Hypoxia, cytokines and stromal recruitment: parallels between pathophysiology of encapsulating peritoneal sclerosis, endometriosis and peritoneal metastasis. Pleura Peritoneum. 2018;3(1):20180103. https:\/\/doi.org\/10.1515\/pp-2018-0103.","journal-title":"Pleura Peritoneum"},{"key":"4732_CR121","doi-asserted-by":"publisher","first-page":"114213","DOI":"10.1016\/j.bcp.2020.114213","volume":"182","author":"C Laussel","year":"2020","unstructured":"Laussel C, L\u00e9on S. Cellular toxicity of the metabolic inhibitor 2-deoxyglucose and associated resistance mechanisms. Biochem Pharmacol. 2020;182:114213. https:\/\/doi.org\/10.1016\/j.bcp.2020.114213.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"4732_CR122","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1159\/000045612","volume":"84","author":"A Shostak","year":"2000","unstructured":"Shostak A, Gotloib L, Kushnier R, Wajsbrot V. Protective effect of pyruvate upon cultured mesothelial cells exposed to 2 mM hydrogen peroxide. Nephron. 2000;84(4):362\u20136.","journal-title":"Nephron"},{"issue":"2","key":"4732_CR123","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/joneph\/16.2.225","volume":"16","author":"AI G\u00fcnal","year":"2003","unstructured":"G\u00fcnal AI, Celiker H, Ustundag B, Akpolat N, Dogukan A, Akcicek F. The effect of oxidative stress inhibition with trimetazidine on the peritoneal alterations induced by hypertonic peritoneal dialysis solution. J Nephrol. 2003;16(2):225\u201330.","journal-title":"J Nephrol"},{"key":"4732_CR124","doi-asserted-by":"publisher","first-page":"642793","DOI":"10.1155\/2014\/642793","volume":"2014","author":"KY Hung","year":"2014","unstructured":"Hung KY, Liu SY, Yang TC, Liao TL, Kao SH. High-dialysate-glucose-induced oxidative stress and mitochondrial-mediated apoptosis in human peritoneal mesothelial cells. Oxid Med Cell Longev. 2014;2014:642793. https:\/\/doi.org\/10.1155\/2014\/642793.","journal-title":"Oxid Med Cell Longev"},{"issue":"6","key":"4732_CR125","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.kint.2018.08.031","volume":"94","author":"A Vychytil","year":"2018","unstructured":"Vychytil A, Herzog R, Probst P, et al. A randomized controlled trial of alanyl-glutamine supplementation in peritoneal dialysis fluid to assess impact on biomarkers of peritoneal health. Kidney Int. 2018;94(6):1227\u201337.","journal-title":"Kidney Int"},{"key":"4732_CR126","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.3389\/fphys.2018.01961","volume":"9","author":"FM Wiesenhofer","year":"2019","unstructured":"Wiesenhofer FM, Herzog R, Boehm M, et al. Targeted metabolomic profiling of peritoneal dialysis effluents shows anti-oxidative capacity of alanyl-glutamine. Front Physiol. 2019;9:1961. https:\/\/doi.org\/10.3389\/fphys.2018.01961.","journal-title":"Front Physiol"},{"issue":"13","key":"4732_CR127","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.7150\/thno.84921","volume":"13","author":"W Su","year":"2023","unstructured":"Su W, Hu Z, Zhong X, et al. Restoration of CPT1A-mediated fatty acid oxidation in mesothelial cells protects against peritoneal fibrosis. Theranostics. 2023;13(13):4482\u201396.","journal-title":"Theranostics"},{"issue":"608","key":"4732_CR128","doi-asserted-by":"publisher","first-page":"eaaz9705","DOI":"10.1126\/scitranslmed.aaz9705","volume":"13","author":"R Herzog","year":"2021","unstructured":"Herzog R, Sacnun JM, Gonz\u00e1lez-Mateo G, et al. Lithium preserves peritoneal membrane integrity by suppressing mesothelial cell \u03b1B-crystallin. Sci Transl Med. 2021;13(608):eaaz9705. https:\/\/doi.org\/10.1126\/scitranslmed.aaz9705.","journal-title":"Sci Transl Med"},{"issue":"1 Suppl 2","key":"4732_CR129","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1053\/ajkd.2001.20762","volume":"37","author":"J Delarue","year":"2001","unstructured":"Delarue J, Maingourd C. Acute metabolic effects of dialysis fluids during CAPD. Am J Kidney Dis. 2001;37(1 Suppl 2):S103\u2013107.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"4732_CR130","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/sdi.13063","volume":"37","author":"S Low","year":"2024","unstructured":"Low S, Liew A. Peritoneal dialysis fluids. Semin Dial. 2024;37(1):10\u201323.","journal-title":"Semin Dial"},{"issue":"15","key":"4732_CR131","doi-asserted-by":"publisher","first-page":"7955","DOI":"10.3390\/ijms22157955","volume":"22","author":"M Bonomini","year":"2021","unstructured":"Bonomini M, Masola V, Procino G, et al. How to improve the biocompatibility of peritoneal dialysis solutions (without jeopardizing the patient\u2019s Health). Int J Mol Sci. 2021;22(15):7955. https:\/\/doi.org\/10.3390\/ijms22157955.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4732_CR132","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1681\/ASN.2004090793","volume":"16","author":"F Finkelstein","year":"2005","unstructured":"Finkelstein F, Healy H, Abu-Alfa A, et al. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol. 2005;16(2):546\u201354.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"4732_CR133","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1046\/j.1523-1755.2003.00887.x","volume":"63","author":"CJ Konings","year":"2003","unstructured":"Konings CJ, Kooman JP, Schonck M, et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int. 2003;63(4):1556\u201363.","journal-title":"Kidney Int"},{"issue":"12","key":"4732_CR134","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1093\/ckj\/sfad155","volume":"16","author":"JE Sanchez","year":"2023","unstructured":"Sanchez JE, Ulloa C, Bueno CM, Astudillo E, Rodr\u00edguez-Su\u00e1rez C. Impact of peritoneal dialysis strategy on technique and patient survival. Clin Kidney J. 2023;16(12):2523\u20139.","journal-title":"Clin Kidney J"},{"issue":"3","key":"4732_CR135","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3747\/pdi.2018.00217","volume":"39","author":"JY Yang","year":"2019","unstructured":"Yang JY, Chen L, Peng YS, Chen YY, Huang JW, Hung KY. Icodextrin is associated with a lower mortality rate in peritoneal dialysis patients. Perit Dial Int. 2019;39(3):252\u201360.","journal-title":"Perit Dial Int"},{"issue":"4","key":"4732_CR136","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/ki.1995.164","volume":"47","author":"JD Kopple","year":"1995","unstructured":"Kopple JD, Bernard D, Messana J, et al. Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int. 1995;47(4):1148\u201357.","journal-title":"Kidney Int"},{"issue":"6","key":"4732_CR137","doi-asserted-by":"publisher","first-page":"445","DOI":"10.5414\/CNP58445","volume":"58","author":"GS Taylor","year":"2002","unstructured":"Taylor GS, Patel V, Spencer S, Fluck RJ, McIntyre CW. Long-term use of 1.1% amino acid dialysis solution in hypoalbuminemic continuous ambulatory peritoneal dialysis patients. Clin Nephrol. 2002;58(6):445\u201350.","journal-title":"Clin Nephrol"},{"issue":"3","key":"4732_CR138","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1111\/j.1523-1755.2004.00879.x","volume":"66","author":"S Mortier","year":"2004","unstructured":"Mortier S, Faict D, Schalkwijk CG, Lameire NH, De Vriese AS. Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int. 2004;66(3):1257\u201365.","journal-title":"Kidney Int"},{"issue":"4","key":"4732_CR139","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1177\/089686080402400414","volume":"24","author":"D Reimann","year":"2004","unstructured":"Reimann D, Dachs D, Meye C, Gross P. Amino acid-based peritoneal dialysis solution stimulates mesothelial nitric oxide production. Perit Dial Int. 2004;24(4):378\u201384.","journal-title":"Perit Dial Int"},{"issue":"11","key":"4732_CR140","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1681\/ASN.2012100987","volume":"24","author":"PK Li","year":"2013","unstructured":"Li PK, Culleton BF, Ariza A, et al. Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients. J Am Soc Nephrol. 2013;24(11):1889\u2013900.","journal-title":"J Am Soc Nephrol"},{"key":"4732_CR141","first-page":"171","volume":"15","author":"E Thodis","year":"1999","unstructured":"Thodis E, Passadakis P, Panagoutsos S, Marinopoulos D, Vargemezis V. Failure of icodextrin to provide adequate ultrafiltration in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial. 1999;15:171\u20134.","journal-title":"Adv Perit Dial"},{"issue":"4","key":"4732_CR142","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1177\/089686080902900404","volume":"29","author":"HL Tjiong","year":"2009","unstructured":"Tjiong HL, Swart R, van den Berg JW, Fieren MW. Amino Acid-based peritoneal dialysis solutions for malnutrition: new perspectives. Perit Dial Int. 2009;29(4):384\u201393.","journal-title":"Perit Dial Int"},{"issue":"5","key":"4732_CR143","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3747\/pdi.2015.00090","volume":"36","author":"T Sikaneta","year":"2016","unstructured":"Sikaneta T, Wu G, Abdolell M, et al. The trio trial - A randomized controlled clinical trial evaluating the effect of a biocompatible peritoneal dialysis solution on residual renal function. Perit Dial Int. 2016;36(5):9\u201310.","journal-title":"Perit Dial Int"},{"issue":"Pt 3","key":"4732_CR144","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1042\/bj3430505","volume":"343","author":"VA Zammit","year":"1999","unstructured":"Zammit VA. The malonyl-CoA-long-chain acyl-CoA axis in the maintenance of mammalian cell function. Biochem J. 1999;343(Pt 3):505\u201315.","journal-title":"Biochem J"},{"issue":"2","key":"4732_CR145","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.pharmthera.2008.08.008","volume":"120","author":"A Arduini","year":"2008","unstructured":"Arduini A, Bonomini M, Savica V, Amato A, Zammit V. Carnitine in metabolic disease: potential for Pharmacological intervention. Pharmacol Ther. 2008;120(2):149\u201356.","journal-title":"Pharmacol Ther"},{"issue":"9","key":"4732_CR146","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1093\/cvr\/cvaf091","volume":"121","author":"BK W\u00f6lnerhanssen","year":"2025","unstructured":"W\u00f6lnerhanssen BK, Meyer-Gerspach AC, Arduini A, et al. Sweeteners: erythritol, xylitol and cardiovascular risk-friend or foe? Cardiovasc Res. 2025;121(9):1319\u201329.","journal-title":"Cardiovasc Res"},{"key":"4732_CR147","first-page":"280","volume":"28","author":"G Bazzato","year":"1982","unstructured":"Bazzato G, Coli U, Landini S, et al. Xylitol as osmotic agent in CAPD: an alternative to glucose for uremic diabetic patients? Trans Am Soc Artif Intern Organs. 1982;28:280\u20136.","journal-title":"Trans Am Soc Artif Intern Organs"},{"issue":"9","key":"4732_CR148","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.tem.2021.06.001","volume":"32","author":"M Lambie","year":"2021","unstructured":"Lambie M, Bonomini M, Davies SJ, Accili D, Arduini A, Zammit V. Insulin resistance in cardiovascular disease, uremia, and peritoneal dialysis. Trends Endocrinol Metab. 2021;32(9):721\u201330.","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"4732_CR149","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/08968608241274106","volume":"45","author":"M Bonomini","year":"2025","unstructured":"Bonomini M, Davies S, Kleophas W, et al. Rationale and design of ELIXIR, a randomized, controlled trial to evaluate efficacy and safety of XyloCore, a glucose-sparing solution for peritoneal dialysis. Perit Dial Int. 2025;45(1):17\u201325.","journal-title":"Perit Dial Int"},{"issue":"9","key":"4732_CR150","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s10157-021-02078-9","volume":"25","author":"N Sugiyama","year":"2021","unstructured":"Sugiyama N, Tawada M, Sun T, et al. Low-GDP, pH-neutral solutions preserve peritoneal endothelial glycocalyx during long-term peritoneal dialysis. Clin Exp Nephrol. 2021;25(9):1035\u201346.","journal-title":"Clin Exp Nephrol"},{"key":"4732_CR151","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.vph.2017.09.002","volume":"100","author":"I Sieve","year":"2018","unstructured":"Sieve I, M\u00fcnster-K\u00fchnel AK, Hilfiker-Kleiner D. Regulation and function of endothelial glycocalyx layer in vascular diseases. Vascul Pharmacol. 2018;100:26\u201333.","journal-title":"Vascul Pharmacol"},{"issue":"2","key":"4732_CR152","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.kint.2018.04.014","volume":"94","author":"PG Blake","year":"2018","unstructured":"Blake PG. Is the peritoneal dialysis biocompatibility hypothesis dead? Kidney Int. 2018;94(2):246\u20138.","journal-title":"Kidney Int"},{"issue":"2","key":"4732_CR153","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.kint.2018.02.022","volume":"94","author":"B Schaefer","year":"2018","unstructured":"Schaefer B, Bartosova M, Macher-Goeppinger S, et al. Neutral pH and low-glucose degradation product dialysis fluids induce major early alterations of the peritoneal membrane in children on peritoneal dialysis. Kidney Int. 2018;94(2):419\u201329.","journal-title":"Kidney Int"},{"issue":"5","key":"4732_CR154","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1177\/089686080302300513","volume":"23","author":"SB Jenkins","year":"2003","unstructured":"Jenkins SB, Wilkie ME. An exploratory study of a novel peritoneal combination dialysate (1.36% glucose\/7.5% icodextrin), demonstrating improved ultrafiltration compared to either component studied alone. Perit Dial Int. 2003;23(5):475\u201380.","journal-title":"Perit Dial Int"},{"issue":"3","key":"4732_CR155","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/089686080702700311","volume":"27","author":"P Freida","year":"2007","unstructured":"Freida P, Galach M, Divino Filho JC, Werynski A, Lindholm B. Combination of crystalloid (glucose) and colloid (icodextrin) osmotic agents markedly enhances peritoneal fluid and solute transport during the long PD dwell. Perit Dial Int. 2007;27(3):267\u201376.","journal-title":"Perit Dial Int"},{"issue":"1","key":"4732_CR156","doi-asserted-by":"publisher","first-page":"100938","DOI":"10.1016\/j.xkme.2024.100938","volume":"7","author":"JL Asher","year":"2024","unstructured":"Asher JL, Ivey-Miranda JB, Maulion C, et al. Development of a novel intraperitoneal Icodextrin\/Dextrose solution for enhanced sodium removal. Kidney Med. 2024;7(1):100938. https:\/\/doi.org\/10.1016\/j.xkme.2024.100938.","journal-title":"Kidney Med"},{"key":"4732_CR157","doi-asserted-by":"publisher","unstructured":"Davy A, \u00d6berg CM, Boyer A, et al. Bimodal solutions in peritoneal dialysis: what can we expect from different glucose volumes added to the icodextrin bag? Data from a simulation procedure. J Nephrol. 2025 Apr;1. https:\/\/doi.org\/10.1007\/s40620-025-02206-8.","DOI":"10.1007\/s40620-025-02206-8"},{"issue":"3","key":"4732_CR158","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3747\/pdi.2016.00206","volume":"37","author":"H Htay","year":"2017","unstructured":"Htay H, Cho Y, Pascoe EM, Darssan D, Hawley C, Johnson DW. BalANZ trial investigators. Predictors of residual renal function decline in peritoneal dialysis patients: the BalANZ trial. Perit Dial Int. 2017;37(3):283\u20139.","journal-title":"Perit Dial Int"},{"key":"4732_CR159","doi-asserted-by":"publisher","unstructured":"Nicdao MA, Wong G, Manera K et al. Incremental compared with full-dose peritoneal dialysis: A cost analysis from a third-party payer perspective in Australia. Perit Dial Int 2025 May 15:8968608251326329. https:\/\/doi.org\/10.1177\/08968608251326329","DOI":"10.1177\/08968608251326329"},{"issue":"1","key":"4732_CR160","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/0896860821996096","volume":"42","author":"MR Marshall","year":"2022","unstructured":"Marshall MR. A systematic review of peritoneal dialysis-related peritonitis rates over time from National or regional population-based registries and databases. Perit Dial Int. 2022;42(1):39\u201347.","journal-title":"Perit Dial Int"},{"issue":"5","key":"4732_CR161","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1177\/08968608231195517","volume":"43","author":"MS Cheetham","year":"2023","unstructured":"Cheetham MS, Cho Y, Krishnasamy R, et al. Multicentre registry analysis of incremental peritoneal dialysis incidence and associations with patient outcomes. Perit Dial Int. 2023;43(5):383\u201394.","journal-title":"Perit Dial Int"},{"issue":"3","key":"4732_CR162","first-page":"2023","volume":"40","author":"L Neri","year":"2023","unstructured":"Neri L, Viglino G, Vizzardi V, et al. Peritoneal dialysis in italy: the 8th GPDP-SIN census 2022. G Ital Nefrol. 2023;40(3):2023\u2013vol3. PMID: 37427898.","journal-title":"G Ital Nefrol"},{"issue":"2","key":"4732_CR163","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/08968608221096556","volume":"43","author":"M Borkum","year":"2023","unstructured":"Borkum M, Jamal A, Suneet Singh R, Levin A. The rationale for the need to study sodium-glucose co-transport 2 inhibitor usage in peritoneal dialysis patients. Perit Dial Int. 2023;43(2):139\u201344.","journal-title":"Perit Dial Int"},{"key":"4732_CR164","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.biopha.2018.10.106","volume":"109","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Fan J, Zheng C, et al. SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2. Biomed Pharmacother. 2019;109:1327\u201338.","journal-title":"Biomed Pharmacother"},{"key":"4732_CR165","doi-asserted-by":"publisher","first-page":"1152611","DOI":"10.3389\/fphar.2023.1152611","volume":"14","author":"J Wang","year":"2023","unstructured":"Wang J, Lv X, A-Ni-Wan AS, et al. Canagliflozin alleviates high glucose-induced peritoneal fibrosis via HIF-1\u03b1 Inhibition. Front Pharmacol. 2023;14:1152611. https:\/\/doi.org\/10.3389\/fphar.2023.1152611.","journal-title":"Front Pharmacol"},{"issue":"2","key":"4732_CR166","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/08968608231161178","volume":"43","author":"VS Sridhar","year":"2023","unstructured":"Sridhar VS, Fraser DJ. SGLT2 inhibition, glucose transport and peritoneal dialysis: finding the sweet spot. Perit Dial Int. 2023;43(2):115\u20138.","journal-title":"Perit Dial Int"},{"issue":"1","key":"4732_CR167","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12882-024-03683-y","volume":"25","author":"JW Lai","year":"2024","unstructured":"Lai JW, Wang CCN, Chou CY. SGLT-2 inhibitors in chronic peritoneal dialysis patients: a follow-up study. BMC Nephrol. 2024;25(1):238. https:\/\/doi.org\/10.1186\/s12882-024-03683-y.","journal-title":"BMC Nephrol"},{"issue":"7","key":"4732_CR168","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10157-024-02467-w","volume":"28","author":"Y Doi","year":"2024","unstructured":"Doi Y, Shinzawa M, Arisato T, et al. Effects of sodium-glucose co-transporter 2 inhibitors on ultrafiltration in patients with peritoneal dialysis: a protocol for a randomized, double-blind, placebo-controlled, crossover trial (EMPOWERED). Clin Exp Nephrol. 2024;28(7):629\u201335.","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"4732_CR169","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1177\/08968608211008095","volume":"41","author":"G Martus","year":"2021","unstructured":"Martus G, Bergling K, de Arteaga J, \u00d6berg CM. SGLT2 Inhibition does not reduce glucose absorption during experimental peritoneal dialysis. Perit Dial Int. 2021;41(4):373\u201380.","journal-title":"Perit Dial Int"},{"issue":"1","key":"4732_CR170","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12882-023-03429-2","volume":"25","author":"Z Hamdan","year":"2024","unstructured":"Hamdan Z, Abdel-Hafez Y, Enaya A, Sarsour A, Kharraz L, Nazzal Z. Dapagliflozin in peritoneal dialysis patients: a pilot study evaluating peritoneal membrane function. BMC Nephrol. 2024;25(1):37. https:\/\/doi.org\/10.1186\/s12882-023-03429-2.","journal-title":"BMC Nephrol"},{"issue":"10","key":"4732_CR171","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1681\/ASN.2022040474","volume":"33","author":"K Bergling","year":"2022","unstructured":"Bergling K, Martus G, \u00d6berg CM. Phloretin improves ultrafiltration and reduces glucose absorption during peritoneal dialysis in rats. J Am Soc Nephrol. 2022;33(10):1857\u201363.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"4732_CR172","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/1744-9987.12319","volume":"19","author":"T Hiramatsu","year":"2015","unstructured":"Hiramatsu T, Ozeki A, Asai K, et al. Liraglutide improves glycemic and blood pressure control and ameliorates progression of left ventricular hypertrophy in patients with type 2 diabetes mellitus on peritoneal dialysis. Ther Apher Dial. 2015;19(6):598\u2013605.","journal-title":"Ther Apher Dial"},{"issue":"3","key":"4732_CR173","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s40620-025-02247-z","volume":"38","author":"P Yavorskiy","year":"2025","unstructured":"Yavorskiy P, Borrelli S, Esposito K, et al. Lesson for the clinical nephrologist: glucagon-like peptide-1 receptor agonists (GLP-1 RA) in a patient with obesity and diabetic kidney disease on peritoneal dialysis. J Nephrol. 2025;38(3):1123\u20135.","journal-title":"J Nephrol"},{"key":"4732_CR174","doi-asserted-by":"publisher","unstructured":"Paribello G, Papa F, Ganzerli MC, Pisani A, Riccio E. Semaglutide in overweight non-diabetic peritoneal dialysis patients: a real-world single-center experience. J Nephrol. 2025 Oct 8. https:\/\/doi.org\/10.1007\/s40620-025-02453-9.","DOI":"10.1007\/s40620-025-02453-9"},{"issue":"8","key":"4732_CR175","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.2215\/CJN.0000000750","volume":"20","author":"BJ Orandi","year":"2025","unstructured":"Orandi BJ, Chen Y, Li Y, et al. GLP-1 receptor agonist Outcomes, Safety, and body mass index change in a National cohort of patients on dialysis. Clin J Am Soc Nephrol. 2025;20(8):1100\u201310.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04732-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04732-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04732-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:38:50Z","timestamp":1781627930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-025-04732-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":175,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4732"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04732-w","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"15 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BL was previously employed by Baxter. Research at Renal Medicine, Karolinska Institutet, is supported by a grant from Vantive to Karolinska Institutet. MLN: Received honoraria for lectures sponsored by Baxter\/Vantive. AB: Received honoraria for lectures sponsored by Baxter\/Vantive. The other authors do not declare any competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}